Microsoft, Adaptive Biotechnologies Work on AI-Enabled Immunology

Microsoft, Adaptive Biotechnologies Work on AI-Enabled Immunology

Microsoft, Adaptive Biotechnologies Work on AI-Enabled Immunology

Microsoft and Adaptive Biotechnologies announced a joint arrangement to leverage artificial intelligence and machine learning with biotechnologies to ultimately decode the human immune system.

Now, Microsoft has revealed its algorithms are to be used as part of a shared project with a company called Adaptive Biotechnologies. Microsoft is also investing an undisclosed sum in the company.

Adaptive will focus their initial work on three classes of disease: Diseases that are often diagnosed in very late stages, like pancreatic and ovarian cancer; autoimmune diseases that are typically hard to diagnose, like multiple sclerosis; and infectious diseases that can remain in a person's system and reoccur, like chronic Lyme disease. From there, the companies will develop a "universal T-cell receptor/antigen map" to detect disease.

Microsoft's corporate vice-president of AI and research, Peter Lee, was equally optimistic in a blogpost about the project. "Microsoft and Adaptive expect this universal map to be the key for the research and development of simple blood-based diagnostics that are broadly accessible to people around the world".

"Some conditions like cancer or autoimmune disorders can be hard to diagnose", Robins added, "but a universal map of the immune system will enable earlier and more accurate diagnosis of disease, potentially helping physicians to connect the dots to understand the relationship between disease states and eventually lead to a better understanding of overall human health".

"Some conditions like cancer or autoimmune disorders can be hard to diagnose, but this universal map of the immune system will enable earlier and more accurate diagnosis of disease, potentially helping physicians to connect the dots to understand the relationship between disease states and eventually lead to a better understanding of overall human health", said Chad Robins, President, CEO and Co-Founder of Adaptive Biotechnologies.

"Some conditions, like cancer or autoimmune disorders, can be hard to diagnose", said Chad Robbins, co-founder and chief executive officer of Adaptive Biotechnologies.

He described the move as a "cornerstone" of his company's Healthcare NExT initiative.

Microsoft and Adaptive Biotechnologies are slated to share more details on their partnership during the JP Morgan Healthcare Conference in San Francisco Jan. 8-11.

Notícias recomendadas

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.